302 related articles for article (PubMed ID: 18823406)
1. Masitinib is safe and effective for the treatment of canine mast cell tumors.
Hahn KA; Ogilvie G; Rusk T; Devauchelle P; Leblanc A; Legendre A; Powers B; Leventhal PS; Kinet JP; Palmerini F; Dubreuil P; Moussy A; Hermine O
J Vet Intern Med; 2008; 22(6):1301-9. PubMed ID: 18823406
[TBL] [Abstract][Full Text] [Related]
2. "Masitinib" is safe and effective for the treatment of canine mast cell tumors.
Gentilini F
J Vet Intern Med; 2010; 24(1):6; author reply 7. PubMed ID: 20391634
[No Abstract] [Full Text] [Related]
3. Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial.
Cadot P; Hensel P; Bensignor E; Hadjaje C; Marignac G; Beco L; Fontaine J; Jamet JF; Georgescu G; Campbell K; Cannon A; Osborn SC; Messinger L; Gogny-Goubert M; Dubreuil P; Moussy A; Hermine O
Vet Dermatol; 2011 Dec; 22(6):554-64. PubMed ID: 21668810
[TBL] [Abstract][Full Text] [Related]
4. Presumed masitinib-induced nephrotic syndrome and azotemia in a dog.
Devine L; Polzin DJ
Can Vet J; 2016 Jul; 57(7):752-6. PubMed ID: 27429464
[TBL] [Abstract][Full Text] [Related]
5. Clinical response of masitinib mesylate in the treatment of canine macroscopic mast cell tumours.
Grant J; North S; Lanore D
J Small Anim Pract; 2016 Jun; 57(6):283-90. PubMed ID: 27136424
[TBL] [Abstract][Full Text] [Related]
6. A retrospective review of treatment and response of high-risk mast cell tumours in dogs.
Miller RL; Van Lelyveld S; Warland J; Dobson JM; Foale RD
Vet Comp Oncol; 2016 Dec; 14(4):361-370. PubMed ID: 25223579
[TBL] [Abstract][Full Text] [Related]
7. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.
Smrkovski OA; Essick L; Rohrbach BW; Legendre AM
Vet Comp Oncol; 2015 Sep; 13(3):314-21. PubMed ID: 23845124
[TBL] [Abstract][Full Text] [Related]
8. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
[TBL] [Abstract][Full Text] [Related]
9. The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs.
Gentilini F; Turba ME; Dally C; Takanosu M; Kurita S; Bonkobara M
BMC Vet Res; 2020 Feb; 16(1):64. PubMed ID: 32075643
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors.
Hahn KA; Legendre AM; Shaw NG; Phillips B; Ogilvie GK; Prescott DM; Atwater SW; Carreras JK; Lana SE; Ladue T; Rusk A; Kinet JP; Dubreuil P; Moussy A; Hermine O
Am J Vet Res; 2010 Nov; 71(11):1354-61. PubMed ID: 21034327
[TBL] [Abstract][Full Text] [Related]
11. Masitinib (AB1010), from canine tumor model to human clinical development: where we are?
Marech I; Patruno R; Zizzo N; Gadaleta C; Introna M; Zito AF; Gadaleta CD; Ranieri G
Crit Rev Oncol Hematol; 2014 Jul; 91(1):98-111. PubMed ID: 24405856
[TBL] [Abstract][Full Text] [Related]
12. Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors.
Davies DR; Wyatt KM; Jardine JE; Robertson ID; Irwin PJ
J Am Anim Hosp Assoc; 2004; 40(2):124-30. PubMed ID: 15007048
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
Le Cesne A; Blay JY; Bui BN; Bouché O; Adenis A; Domont J; Cioffi A; Ray-Coquard I; Lassau N; Bonvalot S; Moussy A; Kinet JP; Hermine O
Eur J Cancer; 2010 May; 46(8):1344-51. PubMed ID: 20211560
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant electrochemotherapy for the treatment of incompletely resected canine mast cell tumors.
Spugnini EP; Vincenzi B; Baldi F; Citro G; Baldi A
Anticancer Res; 2006; 26(6B):4585-9. PubMed ID: 17201181
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and safety of a water-soluble micellar paclitaxel (Paccal Vet) in canine mastocytomas.
Rivera P; Akerlund-Denneberg N; Bergvall K; Kessler M; Rowe A; Willmann M; Persson G; Kastengren Fröberg G; Westberg S; von Euler H
J Small Anim Pract; 2013 Jan; 54(1):20-7. PubMed ID: 23190121
[TBL] [Abstract][Full Text] [Related]
16. Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases.
Cooper M; Tsai X; Bennett P
Vet Comp Oncol; 2009 Sep; 7(3):196-206. PubMed ID: 19691648
[TBL] [Abstract][Full Text] [Related]
17. Safety of masitinib mesylate in healthy cats.
Daly M; Sheppard S; Cohen N; Nabity M; Moussy A; Hermine O; Wilson H
J Vet Intern Med; 2011; 25(2):297-302. PubMed ID: 21314730
[TBL] [Abstract][Full Text] [Related]
18. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs.
Isotani M; Ishida N; Tominaga M; Tamura K; Yagihara H; Ochi S; Kato R; Kobayashi T; Fujita M; Fujino Y; Setoguchi A; Ono K; Washizu T; Bonkobara M
J Vet Intern Med; 2008; 22(4):985-8. PubMed ID: 18564222
[TBL] [Abstract][Full Text] [Related]
19. A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors.
Grant IA; Rodriguez CO; Kent MS; Sfilgoi G; Gordon I; Davis G; Lord L; London CA
J Vet Intern Med; 2008; 22(2):388-93. PubMed ID: 18312556
[TBL] [Abstract][Full Text] [Related]
20. Canine subcutaneous mast cell tumors: cellular proliferation and KIT expression as prognostic indices.
Thompson JJ; Yager JA; Best SJ; Pearl DL; Coomber BL; Torres RN; Kiupel M; Foster RA
Vet Pathol; 2011 Jan; 48(1):169-81. PubMed ID: 21160022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
